Metabolism of ARID1A‑mutated ovarian cancer
Characterize the metabolic landscape of ARID1A-mutated ovarian cancer
This project looks for weak points in how ovarian tumors with ARID1A mutations generate energy to help people with ovarian clear cell carcinoma.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11237566 on NIH RePORTER |
What this research studies
Researchers will compare tumors and tumor cells that do and do not have ARID1A mutations to find mitochondrial protein and function differences. They will use proteomics to map mitochondrial components and perform a CRISPR genetic drop-out screen focused on the mitochondrial electron transport chain. The team will look for specific mitochondrial subunits that ARID1A-deficient cancer cells depend on more than normal cells. Findings may point to precise targets that could be tested as new treatments for ARID1A-mutant cancers.
Who could benefit from this research
Good fit: People with ovarian clear cell carcinoma or other tumors known to carry ARID1A mutations, especially those willing to provide tumor tissue or clinical data, are the most relevant candidates for this line of research.
Not a fit: Patients without ARID1A mutations or those seeking an immediate therapy are unlikely to receive direct clinical benefit from this lab-focused project.
Why it matters
Potential benefit: If successful, this work could reveal new drug targets that block tumor energy use and lead to treatments tailored to ARID1A-mutant ovarian cancers.
How similar studies have performed: Prior studies suggest targeting mitochondrial respiration can work in ARID1A-mutant models, but the comprehensive mitochondrial proteomic profiling and the mETC genetic drop-out screen proposed here are novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Bazzaro, Martina — University of Minnesota
- Study coordinator: Bazzaro, Martina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.